Dr. Reddy's Laboratories Limited RDY NYSE

Dr. Reddy's Laboratories Limited (RDY) generated $46.43B in operating cash flow for fiscal year 2025. After capital expenditures of $34.4B, free cash flow was $12.03B.

Free cash flow margin was 3.7% of revenue. Cash conversion ratio was 0.81x, suggesting some earnings are non-cash.

The company returned $1.39B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (88/100, Pass) — $12.03B (3.7% FCF margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 0.81x suggests some earnings are non-cash items

Overall SharesGrow Score: 83/100 with 6/7 criteria passed.